Rite Aid names Elizabeth “Busy” Burr interim CEO
Rite Aid announced that its board of directors has appointed Elizabeth “Busy” Burr, a member of the company’s board, as interim CEO, effective immediately. Burr’s appointment follows Heyward Donigan’s departure from the company as president and CEO, and as a member of the board. Rite Aid said it has initiated a search to identify a permanent CEO and has retained a leading executive search firm.
Burr has extensive experience in the health industry, and proven expertise in innovation, business strategy, retail and brand management. She previously served as vice president, head of health ventures and chief innovation officer at Humana, a $70 billion for-profit U.S. health insurance company.
Most recently, at Carrot, named a “Most Innovative Company” by Fast Company magazine in 2020, Burr served as president and chief commercial officer, leading the team focused on bringing the company’s digital health solutions to market. Burr previously served as managing director of Citi Ventures and global head of business incubation of Citigroup as well as Entrepreneur-in-Residence at eBay. She also has held various senior leadership roles at Credit Suisse Group AG (formerly Credit Suisse First Boston) and Gap, where she served as vice president of Global Brand Management.
[Read more: 2020 Pharmacy Innovator of the Year: Rite Aid’s RxEvolutionary new approach]
“As the company continues its efforts to enhance its competitive position in this dynamic environment, the board determined and Heyward agreed that now is the right time to identify the next leader of the business," Bruce Bodaken, Rite Aid chairman, stated. "With a deep understanding of the industry and our strategy, the board was unanimous in its belief that Busy is highly qualified to serve as interim CEO while the board conducts a search for a permanent successor. We are fortunate to have someone of her caliber to step into the role and are confident in Busy’s ability to lead the company forward during this transition period.”
Burr said, “Having served as a director since 2019, I have great respect for the important role Rite Aid plays as a full-service pharmacy improving health outcomes for millions of Americans. I will work with the board and management team to realize our vast potential while supporting our thousands of pharmacists and team members who are focused every day on meeting the needs of our communities and customers. With Rite Aid’s well-established brand and its committed and talented team, I look forward to delivering on our business strategy and driving value for all our stakeholders.”
Bodaken continued, “On behalf of the entire board, I want to thank Heyward for her contributions and service to Rite Aid, particularly her efforts in helping to lead Rite Aid throughout the COVID-19 pandemic. We wish her all the best in her future endeavors.”
[Read more: Rite Aid’s Q3 shows growth in Elixir, headwinds in pharmacy margin]
Donigan said, “It has been a privilege to lead Rite Aid and its exceptional team. I am proud of all that we have achieved together, and I believe that the company is well positioned for the future.”
Rite Aid reaffirmed its fiscal year 2023 guidance for total revenues between $23.7 billion and $24.0 billion, net loss between $584 million and $551 million, adjusted EBITDA between $410 million and $440 million and capital expenditures of approximately $225 million.
The company said it continues to expect to generate positive free cash flow in fiscal 2023 and will provide additional detail on its financials and operational progress when it reports its full fourth quarter and fiscal year 2023 results.